STTK News & Events

Reports Q4 revenue $0, consensus $166,670. As of December 31, 2025, cash and cash equivalents and short-term investments were approximately $78.1M, as compared to $73.0M as of December 31, 2024. "SL-325 is now the first DR3 blocking antibody to generate human clinical data, and we are very pleased with the progress we have made in our Phase 1 clinical trial, which is nearly complete. We look forward to sharing the data from this trial in the second quarter, and anticipate initiating our Phase 2 clinical trial in Crohn's disease in the third quarter," said Taylor Schreiber, CEO of Shattuck.

The company said, "As of December 31, 2025, cash and cash equivalents and short-term investments were approximately $78.1M. Shattuck's current cash and cash equivalents and short-term investments, including the gross proceeds from its sale of common stock under its at-the-market offering facility of $21.4M in the Q1, and assuming the full exercise of the outstanding common stock warrants, are expected to fund operations into 2029. This cash runway guidance is based on the Company's current operational plans and excludes any additional capital that may be received, proceeds from business development transactions, and/or additional costs associated with clinical development activities that may be undertaken.